In Situ Hybridization

Roche Diagnostics GmbH and GeneDetect finalize worldwide licensing agreement.

Dr Paul Hughes, CEO of GeneDetect. "Today I am happy to announce that GeneDetect has negotiated a broad license to the valuable Roche Diagnostics GmbH, Digoxigenin/Digoxin patent portfolio for the detection of nucleic acids. This license will allow GeneDetect to release a range of new products incorporating Digoxigenin/Digoxin. We expect these products to become available early in 2006".